Sponsors Can Charge For IND Drugs If They Offer "Significant Advantage"
Executive Summary
FDA's final regulation on charging for IND drugs creates criteria for sponsors to charge for drugs other than their own during clinical trials
You may also be interested in...
Making Expanded Access Programs Work For - Not Against - Your Trial Drug
Providing an investigational drug outside of a controlled trial carries inherent development risks, but it can also be a win-win proposition for patients and sponsors when managed well, veterans of "expanded access" programs say
Making Expanded Access Programs Work For - Not Against - Your Trial Drug
Providing an investigational drug outside of a controlled trial carries inherent development risks, but it can also be a win-win proposition for patients and sponsors when managed well, veterans of "expanded access" programs say
Access To Investigational Drugs Remains Challenge Despite New FDA Rules
FDA has widely publicized ways for patients to get access to investigational trial drugs outside of trials, but there are still many barriers that could hold up implementation in the real world